History

LightSeed LLC is a biotechnology company that is developing technology to: 

1. Prevent cardiac toxicity from chemotherapy, biologics and radiation. 

Cardiac toxicity is a serious consequence of cancer therapies.

https://www.nccn.org/patients/resources/life_with_cancer/managing_symptoms/cardiac_toxicity.aspx

2. Allow selective introduction for gene therapy at a single cell level.

The incidence of doxorubicin cardiomyopathy is about 4% when the dose of doxorubicin is 500–550 mg/m2, 18% when the dose is 551–600 mg/m2 and 36% when the dose exceeds 600 mg/m2.

                Daunorubicin (Cerubidine®),

• Doxorubicin,
• Doxorubicin liposome injection (Doxil®),
• Epirubicin (Ellence®),
• Idarubicin (Idamycin® PFS), and
• Valrubicin (Valstar®)

Adverse events from immune checkpoint inhibitors (ICI) are a common occurrence, cardiotoxic effects are uncommon, but are often serious complications with a relatively high mortality. Toxicity includes  myocarditis, Takotsubo syndrome, acute coronary syndrome and pericardial disease.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736791/

.Targeted therapy drugs that can cause damage to the heart include 

trastuzumab (Herceptin®), 

• bevacizumab (Avastin®), 
• lapatinib (Tykerb®), 
• sunitinib (Sutent®), 
• sorafenib (Nexavar®). 

These drugs are used in a variety of cancer types..

.